Loading
Nuclear medicine leader who co-led VISION and runs one of the world's largest theranostics programmes.
Ken Herrmann was a lead investigator of VISION and of the German multicentre 177Lu-PSMA-617 registry, and leads the Essen theranostics centre that has treated thousands of patients with PSMA and somatostatin receptor radioligands. He has chaired the EANM oncology committee, co-authored the Lancet Oncology series on theranostics, and leads trials of alpha emitters and new targets such as FAP.
| Title | Journal | Year |
|---|---|---|
| Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer (VISION) | NEJM | 2021 |
| Radiotheranostics: a roadmap for future development | Lancet Oncology | 2020 |
Shares VISION, VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer, Lutetium-177 vipivotide tetraxetan, PSMA and the tag radioligand.
Shares VISION, VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer, Lutetium-177 vipivotide tetraxetan, PSMA.
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters) and the tag radioligand.
Shares European Association of Nuclear Medicine, FAPI PET, FAP, Lutetium-177 vipivotide tetraxetan.
Shares FAPI PET, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, PSMA PET.
Shares VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer, Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET.
Shares FAPI PET, FAP, Lutetium-177 vipivotide tetraxetan, PSMA.
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/